EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas

Jorge H Hernandez-Felix iD, Mahshid Golagha, Abhishek Jha, Diana Varghese, Simona Grozinsky-Glasberg iD, Rachel Riechelmann iD, Nicola Fazio iD, Marianne Pavel, Frank I Lin, David Taïeb iD, Karel Pacak, Jaydira Del Rivero iD

Endocrine-Related Cancer · 2026

DOI: 10.1530/erc-26-0036 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, 2026. Verfasst von Jorge H Hernandez-Felix und 11 weiteren Autor:innen. Beteiligte Einrichtung: Developmental Therapeutics Clinic, National Cancer Institute (NCI), National Institutes of Health , Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Paraganglioma, Pheochromocytoma, Radiopharmaceuticals, Molecular Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors of neural crest origin that exhibit wide clinical and biological heterogeneity. While surgical resection remains the only curative option, many patients have unresectable or metastatic progressive disease with uncontrolled secretion, requiring alternative management strategies. Advances in genetics have revealed germline pathogenic variants in up to 30–40% of cases, refining tumor classification and guiding the use of molecularly targeted imaging. Functional imaging modalities, such as 68Ga or 64Cu-DOTA-SSA (somatostatin analogs), 18F-FDOPA, 18F-FDG and 123I-MIBG, exploit tumor biology, such as somatostatin receptor expression, catecholamine biosynthesis and altered glucose metabolism. These approaches not only improve diagnostic accuracy but also help in prognosis and selection to therapies. Radioligand therapies have emerged as a pivotal option in advanced PPGLs. High-specific-activity 131I-MIBG has demonstrated durable disease control, symptomatic improvement and favorable safety in multicenter studies, leading to US Food and Drug Administration approval for metastatic PPGL, although currently not commercially available. More recently, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE has shown disease control rates of 80–100% in prospective and retrospective trials, with outcomes enhanced by standardized dosing strategies. Ongoing studies are evaluating PRRT in genetically defined subgroups and exploring synergistic combinations, including radiosensitizing approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParagangliomaPheochromocytomaRadiopharmaceuticalsMolecular ImagingAdrenal Gland NeoplasmsHumansAnimals

Stichwörter der Autor:innen

123I-MIBG131I-MIBG177Lu-DOTATATE18F-FDG18F-FDOPA68Ga-DOTATATEPRRTparagangliomapheochromocytomaradionuclide therapy

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Developmental Therapeutics Clinic, National Cancer Institute (NCI), National Institutes of Health , Bethesda, Maryland, USA.
  • Departament of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City, Mexico.
  • Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, Maryland, USA.
  • Neuroendocrine Tumor Unit, ENETS Center of Excellence, Division of Medicine, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem, Israel.
  • Department of Clinical Oncology, AC Camargo Cancer Center , São Paulo, Brazil.
  • European Institute of Oncology (IEO), IRCCS, Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors , Milan, Italy.

ORCID-Profile: Jorge H Hernandez-Felix, Simona Grozinsky-Glasberg, Rachel Riechelmann, Nicola Fazio, David Taïeb, Jaydira Del Rivero

Zitieren

APA

Hernandez-Felix, J. H., Golagha, M., Jha, A., Varghese, D., Grozinsky-Glasberg, S., Riechelmann, R., Fazio, N., Pavel, M., Lin, F. I., Taïeb, D., Pacak, K., & Del Rivero, J. (2026). Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas. Endocrine-Related Cancer. https://doi.org/10.1530/erc-26-0036

Vancouver

Hernandez-Felix JH, Golagha M, Jha A, Varghese D, Grozinsky-Glasberg S, Riechelmann R, et al. Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas. Endocrine-Related Cancer. 2026. doi:10.1530/erc-26-0036

BibTeX
@article{HernandezFelix2026,
  author = {Hernandez-Felix, Jorge H and Golagha, Mahshid and Jha, Abhishek and Varghese, Diana and Grozinsky-Glasberg, Simona and Riechelmann, Rachel and Fazio, Nicola and Pavel, Marianne and Lin, Frank I and Taïeb, David and Pacak, Karel and Del Rivero, Jaydira},
  title = {Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  doi = {10.1530/erc-26-0036}
}
Kostenlos starten →